ScholarIQanswers from OpenAlex & ORCID
Hiroaki Akamatsu
ResearcherPublications, citations & collaboration network
Hiroaki Akamatsu is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Hiroaki Akamatsu have?
ScholarIQindexed works
Hiroaki Akamatsu has 348 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hiroaki Akamatsu have?
ScholarIQcitation count
Hiroaki Akamatsu has 9,690 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Hiroaki Akamatsu?
ScholarIQh-index
Hiroaki Akamatsu has an h-index of 38 in OpenAlex.
What is the i10-index of Hiroaki Akamatsu?
ScholarIQi10-index
Hiroaki Akamatsu has an i10-index of 106 in OpenAlex.
What is the ORCID of Hiroaki Akamatsu?
ScholarIQorcid
The ORCID for Hiroaki Akamatsu is on the source record.
What is the OpenAlex record for Hiroaki Akamatsu?
ScholarIQopenalex
The OpenAlex for Hiroaki Akamatsu is on the source record.
What are the most-cited papers on Hiroaki Akamatsu?
ScholarIQmost cited works
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
Tony Mok, Yi‐Long Wu, Myung‐Ju Ahn, Marina Chiara Garassino, Hye Ryun Kim, Suresh S. Ramalingam, Frances A. Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S.M.E. Theelen, Chee Khoon Lee, Martin Sebastian, Alison Templeton, Helen Mann, Marcelo Marotti, Serban Ghiorghiu, Vassiliki A. Papadimitrakopoulou
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
John V. Heymach, David H. Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Gálffy, Maximilian J. Hochmair, Thomas Winder, Р. А. Зуков, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang‐Yun Lee, Lorenzo Antonuzzo, Zsolt Pápai-Székely, Hiroaki Akamatsu, Bivas Biswas, Alexander I. Spira, Jeffrey Crawford, Ha Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
Myung‐Ju Ahn, Byoung Chul Cho, Enriqueta Felip, Ippokratis Korantzis, Kadoaki Ohashi, Margarita Majem, Óscar Juan, Sabin Handzhiev, Hiroki Izumi, Jong Seok Lee, Rafał Dziadziuszko, Jürgen Wolf, Fiona Blackhall, Martin Reck, Jean Bustamante Alvarez, Horst-Dieter Hummel, Anne‐Marie C. Dingemans, Jacob Sands, Hiroaki Akamatsu, Taofeek K. Owonikoko, Suresh S. Ramalingam, Hossein Borghaei, Melissa L. Johnson, Shuang Huang, Sujoy Mukherjee, Mukul Minocha, Tony Jiang, Pablo Martínez, Erik S. Anderson, Luis Paz‐Ares
Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
Koichi Sato, Hiroaki Akamatsu, Eriko Murakami, Seigo Sasaki, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Keiichiro Akamatsu, Yasuhiro Koh, Hiroki Ueda, Masanori Nakanishi, Nobuyuki Yamamoto
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
Vassiliki A. Papadimitrakopoulou, Tony Mok, Ji‐Youn Han, Myung‐Ju Ahn, Angelo Delmonte, Suresh S. Ramalingam, Seung‐Whan Kim, Frances A. Shepherd, Janessa Laskin, Yong He, Hiroaki Akamatsu, Willemijn S.M.E. Theelen, Wu‐Chou Su, Thomas John, Martin Sebastian, Helen Mann, Michele Miranda, Gianluca Laus, Yuri Rukazenkov, Yi‐Long Wu